Endometrial Development
Conditions
Brief summary
Women in assisted reproduction treatment they receive own or donated embryos and presenting an endometrial development less than 5 mm despite having received treatment with estrogen therapy knowing the clinical value of using the PRGF-Endoret therapy and endometrial level applications to improve endometrial thickness endometrial preparations for embryo transfer.
Interventions
DRUGGrowth Factor, Platelet-Derived
0,5 mL, vaginal use , 3 dose number
Sponsors
IVI Bilbao
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 49 Years
Healthy volunteers
No
Inclusion criteria
* Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type. * Less than 5mm despite 10 days with standard doses of estrogen therapy (6mg / 24h) Endometrio
Exclusion criteria
* History of pelvic inflammatory disease * Risk of infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the growth of endometrial thickness | During ovarian stimulation protocol 8-12 days | The endometrial thickness will be measured by vaginal ultrasound. Endometrium less than 5 mm will be treated |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Analyze the impact of using platelet plasma on rates of implantation and pregnancy. | During ovarian stimulation protocol 8-12 days | The biochemical determination of the hormone ßhcg will be performed 12 days after embryo transfer |
Countries
Spain
Outcome results
None listed